Malignant neoplasm of urinary bladder
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
PATIENT SUMMARY: We propose that APOBEC-mediated mutagenesis can generate clinically relevant driver mutations even within suboptimal motifs, such as in the case of FGFR3 S249C, one of the most common mutations in bladder cancer.
|
30975452 |
2019 |
Malignant neoplasm of urinary bladder
|
0.800 |
Biomarker
|
disease |
BEFREE |
Regarding the association between mutated FGFR3 and bladder cancer, we found an OR 31 95% CI (15-64).
|
31028457 |
2019 |
Malignant neoplasm of urinary bladder
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Silencing or inhibition of mutant FGFR3 in bladder cancer cell lines is associated with decreased malignant potential, confirming its important driver role in UC.
|
30952872 |
2019 |
Malignant neoplasm of urinary bladder
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Usefulness of droplet digital PCR and Sanger sequencing for detection of FGFR3 mutation in bladder cancer.
|
31377167 |
2019 |
Malignant neoplasm of urinary bladder
|
0.800 |
Biomarker
|
disease |
BEFREE |
Hsa_circ_0068871 regulates the miR-181a-5p/FGFR3 axis and activates STAT3 to promote BCa progression, and it may serve as a potential biomarker.
|
30999937 |
2019 |
Malignant neoplasm of urinary bladder
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The FGFR3<sup>S249C</sup> mutation may therefore be used as a predictor of chemosensitivity in patients with BCa.
|
31316618 |
2019 |
Malignant neoplasm of urinary bladder
|
0.800 |
Biomarker
|
disease |
BEFREE |
In particular the Survivin-CD44 correlation was associated to HG FGFR3 wild type BCs (p = 0.0045).
|
30650148 |
2019 |
Malignant neoplasm of urinary bladder
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Recent precision medicine has shown that mutations in BC are frequently observed in FGFR3, RAS and PIK3CA genes, all of which correlate with RAS signaling networks.
|
31066120 |
2019 |
Malignant neoplasm of urinary bladder
|
0.800 |
Biomarker
|
disease |
BEFREE |
The aim of this paper was to report the most pivotal trials that evaluated different families of targeted therapy in the treatment of BC, according to their biomarkers (FGFR3, EGFR, HER2, VEGF and PI3K/AKT/mTOR).
|
30977669 |
2019 |
Malignant neoplasm of urinary bladder
|
0.800 |
Biomarker
|
disease |
BEFREE |
Human bladder cancer T24 and 5637 cell lines were transiently transfected with FGFR3-AS1-specific siRNA or negative control siRNA.
|
29226855 |
2018 |
Malignant neoplasm of urinary bladder
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.
|
29941343 |
2018 |
Malignant neoplasm of urinary bladder
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
We discovered a positive feedback loop, in which the activation of p38 and AKT downstream from the altered FGFR3 upregulates <i>MYC</i> mRNA levels and stabilizes MYC protein, respectively, leading to the accumulation of MYC, which directly upregulates <i>FGFR3</i> expression by binding to active enhancers upstream from <i>FGFR3</i> Disruption of this FGFR3/MYC loop in bladder cancer cell lines by treatment with FGFR3, p38, AKT, or BET bromodomain inhibitors (JQ1) preventing <i>MYC</i> transcription decreased cell viability <i>in vitro</i> and tumor growth <i>in vivo</i> A relevance of this loop to human bladder tumors was supported by the positive correlation between <i>FGFR3</i> and <i>MYC</i> levels in tumors bearing <i>FGFR3</i> mutations, and the decrease in FGFR3 and MYC levels following anti-FGFR treatment in a PDX model bearing an <i>FGFR3</i> mutation.
|
29463565 |
2018 |
Malignant neoplasm of urinary bladder
|
0.800 |
Biomarker
|
disease |
BEFREE |
Here we show that HDAC6 loss or inhibition reduces FGFR3 accumulation in cells made tumorigenic by ectopic expression of a mutant activated version of FGFR3 together with the MYC oncoprotein and in a bladder cancer cell line whose tumorigenicity is dependent on expression of a translocated version of FGFR3.
|
29423038 |
2018 |
Malignant neoplasm of urinary bladder
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The GSE41035 dataset downloaded from Gene Expression Omnibus was used to identify the differentially expressed genes (DEGs) between bladder cancer cell line RT112 with or without depletion of FGFR3, and gene ontology enrichment analysis was performed.
|
28320388 |
2017 |
Malignant neoplasm of urinary bladder
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Further investigation showed that FGFR3 knockdown resulted in downregulation of DAPK1 in bladder cancer cell line, suggesting that FGFR3 may be an upstream factor of DAPK1.
|
28388658 |
2017 |
Malignant neoplasm of urinary bladder
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Increased levels of FGFR3 and PIK3CA mutated DNA in urine and plasma are indicative of later progression and metastasis in bladder cancer.
|
28069289 |
2017 |
Malignant neoplasm of urinary bladder
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The present study examined the utility of fibroblast growth factor receptor 3 (<i>FGFR3</i>) mutation status and gene expression as a prognostic marker in primary pT1 bladder cancer (BC).
|
28927152 |
2017 |
Malignant neoplasm of urinary bladder
|
0.800 |
Biomarker
|
disease |
BEFREE |
FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
|
28049011 |
2017 |
Malignant neoplasm of urinary bladder
|
0.800 |
Biomarker
|
disease |
BEFREE |
FGFR3-TACC3 fusion transcripts were identified by RNA-FISH and RT-PCR in mouse xenograft FFPE tissues using the human BC cell lines RT112 and RT4.
|
27930669 |
2016 |
Malignant neoplasm of urinary bladder
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of endogenous FGFR3 impaired the activity of daidzein against bladder cancer, which suggested that the effect of daidzein was mainly mediated by FGFR3 pathway.
|
27268915 |
2016 |
Malignant neoplasm of urinary bladder
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer.
|
27356691 |
2016 |
Malignant neoplasm of urinary bladder
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Search terms included 'FGFR3 genomic alterations' and 'urothelial cancer' or 'bladder cancer'.
|
27271022 |
2016 |
Malignant neoplasm of urinary bladder
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In non-invasive BC, these mutations were related to high risk and grade (p<0.0001) as well as progression to muscle-invasive disease (p=0.01), whereas FGFR3 mutations were observed in low-grade BC (p=0.02) and patients with recurrences (p=0.05).
|
27611947 |
2016 |
Malignant neoplasm of urinary bladder
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 mutations are common in low-grade BC, while TP53 mutation or loss of RB1 is associated with muscle-invasive BC.
|
26924873 |
2016 |
Malignant neoplasm of urinary bladder
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Our findings are consistent with the results of the TCGA data set for the "squamous-like" subtype of bladder cancer (n = 85), which revealed reduced overall expression of FGFR1 and FGFR2 in tumors compared to normal tissue, while expression of FGFR3 remained high.
|
27669755 |
2016 |